Effect of Food on the Pharmacokinetics of the Integrase Inhibitor DolutegravirSONG, Ivy; BORLAND, Julie; SHUGUANG CHEN et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 3, pp 1627-1629, issn 0066-4804, 3 p.Article

Quinoline-based HIV Integrasc Inhibitors : The Development of Novel Inhibitors for the Treatment of HIV InfectionMUSIOL, Robert.Current pharmaceutical design (Print). 2013, Vol 19, Num 10, pp 1835-1849, issn 1381-6128, 15 p.Article

Integrase Inhibitors Effective against Human T-Cell Leukemia Virus Type 1MUHAMMAD ESA SEEGULAML; RATNER, Lee.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 5, pp 2011-2017, issn 0066-4804, 7 p.Article

Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimenROQUEBERT, Benedicte; BLUM, Laurent; COLLIN, Gilles et al.AIDS (London). 2008, Vol 22, Num 15, pp 2045-2046, issn 0269-9370, 2 p.Article

Exacerbation of depression associated with starting raltegravir : a report of four casesHARRIS, Marianne; LARSEN, Gerene; MONTANER, Julio S. G et al.AIDS (London). 2008, Vol 22, Num 14, pp 1890-1892, issn 0269-9370, 3 p.Article

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor ElvitegravirRAMANATHAN, Srinivasan; MATHIAS, Anita A; GERMAN, Polina et al.Clinical pharmacokinetics. 2011, Vol 50, Num 4, pp 229-244, issn 0312-5963, 16 p.Article

Raltegravir-induced cerebellar ataxiaREISS, Kim A; BAILEY, Justin R; PHAM, Paul A et al.AIDS (London). 2010, Vol 24, Num 17, issn 0269-9370, p. 2757Article

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744FORD, Susan L; GOULD, Elizabeth; SHUGUANG CHEN et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 11, pp 5472-5477, issn 0066-4804, 6 p.Article

Divalent Metals and pH Alter Raltegravir Disposition In VitroMOSS, Darren M; SICCARDI, Marco; MURPHY, Matthew et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 6, pp 3020-3026, issn 0066-4804, 7 p.Article

Characterization of Binding of Raltegravir to Plasma ProteinsBARAU, Caroline; FURLAN, Valérie; YAZDANPANAH, Yazdan et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 10, pp 5147-5150, issn 0066-4804, 4 p.Article

Severe rhabdomyolysis associated with raltegravir useZEMBOWER, Teresa R; GERZENSHTEIN, Lana; COLEMAN, Karen et al.AIDS (London). 2008, Vol 22, Num 11, pp 1382-1384, issn 0269-9370, 3 p.Article

Update on Raltegravir and the Development of New Integrase Strand Transfer InhibitorsLEE SHAMROE, Caitlin; BOOKSTAVER, Paul Brandon; ROKAS, Kristina E. E et al.Southern medical journal (Birmingham, Ala. Print). 2012, Vol 105, Num 7, pp 370-378, issn 0038-4348, 9 p.Article

Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tubeTAEGTMEYER, Anne B; MÜLLER, Veronique; KOVARI, Helen et al.AIDS (London). 2011, Vol 25, Num 10, pp 1339-1341, issn 0269-9370, 3 p.Article

Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing RaltegravirCANDUCCI, Filippo; CERESOLA, Elisa R; BOERI, Enzo et al.The Journal of infectious diseases. 2011, Vol 204, Num 11, pp 1811-1815, issn 0022-1899, 5 p.Article

Raltegravir Penetration in Seminal Plasma of Healthy VolunteersCALCAGNO, Andrea; BONORA, Stefano; D'AVOLIO, Antonio et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 6, pp 2744-2745, issn 0066-4804, 2 p.Article

Effect of Prednisone on the Pharmacokinetics of the Integrase Inhibitor DolutegravirSONG, Ivy H; BORLAND, Julie; SHUGUANG CHEN et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 9, pp 4394-4397, issn 0066-4804, 4 p.Article

Next-Generation Integrase Inhibitors: Where to After Raltegravir?KARMON, Sharon L.Drugs (Basel). 2013, Vol 73, Num 3, pp 213-228, issn 0012-6667, 16 p.Article

Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational studyMADEDDU, Giordano; MENZAGHI, Barbara; RICCI, Elena et al.AIDS (London). 2012, Vol 26, Num 18, pp 2412-2415, issn 0269-9370, 4 p.Article

Pharmacokinetics of Raltegravir in Individuals With UGT1 A1 PolymorphismsWENNING, L. A; POETRY, A. S; LUNDE, N. M et al.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 6, pp 623-627, issn 0009-9236, 5 p.Article

La résistance du VIH aux inhibiteurs de l'intégrase = HIV resistance to integrase inhibitorsROQUEBERT, Bénédicte; MARCELIN, Anne-Geneviève; DESCAMPS, Diane et al.Virologie (Montrouge). 2009, Vol 13, Num MAI, issn 1267-8694, S35-S42, NSArticle

Actualités dans la prise en charge du VIH-1CHAIX, Marie-Laure; GHOSN, Jade.MT. Médecine thérapeutique. 2010, Vol 16, Num 1, pp 39-46, issn 1264-6520, 8 p.Article

Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248ANDRADE, Adriana; ROSENKRANZ, Susan L; FLEXNER, Charles et al.The Journal of infectious diseases. 2013, Vol 208, Num 6, pp 884-891, issn 0022-1899, 8 p.Article

Short-Course Raltegravir Intensification Does Not Increase 2 Long Terminal Repeat Episomal HIV-1 DNA in Patients on Effective Antiretroviral TherapyBESSON, Guillaume J; MCMAHON, Deborah; MALDARELLI, Frank et al.Clinical infectious diseases. 2012, Vol 54, Num 3, pp 451-453, issn 1058-4838, 3 p.Article

Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawalCHARPENTIER, Charlotte; LARROUY, Lucile; MATHERON, Sophie et al.Antiviral therapy (London). 2011, Vol 16, Num 6, pp 937-940, issn 1359-6535, 4 p.Article

Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patientsCABY, Fabienne; VALIN, Nadia; PACANOWSKI, Jérome et al.Scandinavian journal of infectious diseases. 2010, Vol 42, Num 6-7, pp 527-532, issn 0036-5548, 6 p.Article